The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis
Clinical Gastroenterology and Hepatology · 2026-01 · 24 (1) · 131-140
DOI: 10.1016/j.cgh.2025.04.030 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-01. Verfasst von Lukas Hartl und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic La…. Hauptthemen laut MEDLINE: Biomarkers, Glycopeptides, Inflammation, Liver Cirrhosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna, Gilead Sciences, Siemens.
Abstract (Originalsprache)
BACKGROUND & AIMS: Copeptin, an arginine-vasopressin biomarker, may confer prognostic information in patients with advanced chronic liver disease (ACLD). METHODS: Patients with ACLD included in the Vienna Cirrhosis Study (NCT03267615) between January 2017 and April 2023 and available copeptin levels were prospectively recruited and classified into 6 predefined clinical ACLD stages from S0 (subclinical portal hypertension) to S5 (further decompensation). A prognostic score (MELD-copeptin score) in patients with decompensated ACLD (dACLD) was developed in a derivation cohort (n = 150) and validated in an internal (n = 148) and an external validation cohort (n = 771). RESULTS: Among 475 patients with ACLD, 177 were compensated, whereas 298 were decompensated. Median levels of copeptin increased with progressive ACLD severity (S0, 7.5 pmol/L vs S5, 14.3 pmol/L; P < .001). Copeptin (adjusted Beta, 0.10; P < .001) was independently associated with interleukin-6 levels in dACLD. In dACLD, copeptin was linked to higher risk of further decompensation (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P = .039), acute-on-chronic liver failure (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.01-1.02; P < .001), and liver-related death (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.01-1.02; P < .001) independently of relevant cofactors. The MELD-copeptin score yielded higher area under the receiver operating characteristics (AUROCs) for liver-related events than the MELD-Na score in the internal validation cohort, accurately predicting liver-related death at 6 months (AUROC, 0.777 vs MELD-Na, 0.673), 1 year (AUROC, 0.784 vs MELD-Na, 0.661), and 2 years of follow-up (AUROC, 0.741 vs MELD-Na, 0.636). Similarly, the MELD-copeptin score consistently yielded higher AUROCS for the development of liver-related death and acute-on-chronic liver failure at 3, 6, and 12 months of follow-up in the external validation cohort. CONCLUSIONS: In patients with dACLD, copeptin is independently linked to systemic inflammation. The MELD-copeptin score identifies patients with dACLD at risk for impaired clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine…
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Hepatology, University Hospital of Besançon, Besançon, France.
- European Foundation for the Study of Chronic Liver Failure (EF CLIF) and Grifols Chair Program, Barcelona, Spain; Université Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; AP-HP, Hô…
- European Foundation for the Study of Chronic Liver Failure (EF CLIF) and Grifols Chair Program, Barcelona, Spain; Department of Internal Medicine B, University of Münster, Münster, Germany.
Förderung
- Medical University of Vienna
- Gilead Sciences
- Siemens
Zitieren
APA
Hartl, L., Hintersteininger, M., Simbrunner, B., Jachs, M., Hofer, B. S., Bauer, D. J. M., Dominik, N., Schwarz, M., Balcar, L., Kramer, G., Kerbert, A. J. C., Coenraad, M. J., Thevenot, T., Moreau, R., Trebicka, J., Clària, J., Marculescu, R., Trauner, M., Mandorfer, M., & Reiberger, T. (2026). The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 24(1), 131-140. https://doi.org/10.1016/j.cgh.2025.04.030
Vancouver
Hartl L, Hintersteininger M, Simbrunner B, Jachs M, Hofer BS, Bauer DJM, et al. The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2026;24(1):131-140. doi:10.1016/j.cgh.2025.04.030
BibTeX
@article{Hartl2026,
author = {Hartl, Lukas and Hintersteininger, Marlene and Simbrunner, Benedikt and Jachs, Mathias and Hofer, Benedikt Silvester and Bauer, David Josef Maria and Dominik, Nina and Schwarz, Michael and Balcar, Lorenz and Kramer, Georg and Kerbert, Annarein J C and Coenraad, Minneke J and Thevenot, Thierry and Moreau, Richard and Trebicka, Jonel and Clària, Joan and Marculescu, Rodrig and Trauner, Michael and Mandorfer, Mattias and Reiberger, Thomas},
title = {The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {1},
pages = {131--140},
doi = {10.1016/j.cgh.2025.04.030}
}
EUVIMED